Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/16/21
06/16
04:55
06/16/21
04:55
APTO

Aptose Biosciences

$3.50 /

-0.21 (-5.66%)

, MBIO

Mustang Bio

$3.57 /

-0.115 (-3.13%)

, QURE

uniQure

$34.46 /

-0.43 (-1.23%)

, RIGL

Rigel Pharmaceuticals

$4.27 /

-0.1 (-2.29%)

, MGTA

Magenta Therapeutics

$11.38 /

+0.05 (+0.44%)

, MEIP

MEI Pharma

$3.10 /

-0.15 (-4.62%)

, CRIS

Curis

$7.61 /

-0.44 (-5.47%)

, XLRN

Acceleron

$128.63 /

-2.39 (-1.82%)

, EPZM

Epizyme

$8.79 /

-0.025 (-0.28%)

, INCY

Incyte

$82.69 /

+0.11 (+0.13%)

, ORTX

Orchard Therapeutics

$4.85 /

-0.19 (-3.77%)

, TGTX

TG Therapeutics

$37.42 /

-0.88 (-2.30%)

, EQ

Equillium

$6.05 /

+0.05 (+0.83%)

, JAZZ

Jazz Pharmaceuticals

$183.42 /

-2.7 (-1.45%)

, VRTX

Vertex Pharmaceuticals

$188.94 /

-5.87 (-3.01%)

, SGEN

Seagen

$153.20 /

-2.99 (-1.91%)

, IMRA

Imara

$8.26 /

-0.44 (-5.06%)

, GBT

Global Blood Therapeutics

$39.60 /

-0.65 (-1.61%)

, BGNE

BeiGene

$332.97 /

-9.75 (-2.84%)

, APLS

Apellis

$60.63 /

-4.27 (-6.58%)

, AGIO

Agios Pharmaceuticals

$58.23 /

+0.04 (+0.07%)

, FMTX

Forma Therapeutics

$24.13 /

-0.09 (-0.37%)

, KROS

Keros Therapeutics

$52.55 /

-0.455 (-0.86%)

, CYAD

Celyad

$5.44 /

+0.03 (+0.55%)

, ALXN

Alexion

$181.90 /

+0.25 (+0.14%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CYAD Celyad
$5.44 /

+0.03 (+0.55%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.46 /

-0.43 (-1.23%)

06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$7.61 /

-0.44 (-5.47%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.69 /

+0.11 (+0.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.05 /

+0.05 (+0.83%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$153.20 /

-2.99 (-1.91%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.26 /

-0.44 (-5.06%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$60.63 /

-4.27 (-6.58%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.44 /

+0.03 (+0.55%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.90 /

+0.25 (+0.14%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

Yesterday
Recommendations
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler » 12:22
06/15/21
06/15
12:22
06/15/21
12:22
JNCE

Jounce Therapeutics

$7.84 /

+0.87 (+12.48%)

, GILD

Gilead

$67.89 /

-0.26 (-0.38%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $20 price target on Jounce Therapeutics (JNCE), which will receive a $25M milestone from partner Gilead (GILD) for IND clearance for anti-CCR8 antibody GS-1811. Jounce, which expects to initiate eight expansion cohorts in 2H21, now holds pro forma cash of roughly $296M to advance its innovative I-O pipeline, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
GILD Gilead
$67.89 /

-0.26 (-0.38%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

  • 10
    Mar
GILD Gilead
$67.89 /

-0.26 (-0.38%)

JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

Hot Stocks
Canadian Pacific: SMART-TD urges STB to reject CN's proposed use of voting trust » 08:33
06/15/21
06/15
08:33
06/15/21
08:33
CP

Canadian Pacific

$80.61 /

+0.37 (+0.46%)

, CNI

Canadian National

$111.05 /

+0.72 (+0.65%)

, KSU

Kansas City Southern

$292.28 /

-1.645 (-0.56%)

Canadian Pacific Railway…

Canadian Pacific Railway (CP) announced that SMART-Transportation Division, North America's largest railroad operating union, has submitted a letter urging the Surface Transportation Board to reject Canadian National's (CNI) proposed use of a voting trust. SMART-TD joins a growing list of shippers, communities, labor unions and other stakeholders who have voiced opposition to CN's voting trust as part of its proposal to combine with Kansas City Southern (KSU). In a letter to the STB, SMART-TD President Jeremy Ferguson writes: "The approval of the CN voting trust by the STB would be risky for the railway industry and quite possibly will negatively impact our involved SMART-TD members. Approval of the CN voting trust proposal would harm employees of both KCS and CN due to the amount of debt CN will carry and the real possibility that the CN transaction would fail the regulatory test in the end. The CN/KCS transaction is the opposite of an end-to-end merger and would be anti-competitive due to the overlap of existing rail lines and affected customers. The CN already has a high capacity mainline route from Chicago, IL straight to New Orleans, LA, therefore with CN acquiring KCS there would be no need for parallel routes such as the KCS line from Kansas City through to New Orleans. If the CN voting trust and proposed merger were granted approval, we fully expect significant job losses on either CN or KCS because ultimately the transaction would require either a sale or abandonment of duplicative rail lines. The consequences for SMART-TD members would be uncertain, adverse, and certainly contrary to the public interest." In contrast, the SMART-TD letter says of Canadian Pacific's proposed combination with KCS: "we anticipate growth in both rail businesses and jobs for SMART-TD members."

ShowHide Related Items >><<
CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

05/27/21 Scotiabank
Canadian Pacific price target raised to C$108 from C$96 at Scotiabank
05/26/21 Desjardins
Canadian Pacific price target adjusted to reflect 5-for-1 split at Desjardins
05/25/21 Evercore ISI
Kansas City Southern resumed at In Line from Outperform at Evercore ISI
05/25/21 Evercore ISI
Canadian Pacific resumed with an In Line at Evercore ISI
CNI Canadian National
$111.05 /

+0.72 (+0.65%)

05/28/21 UBS
Canadian National upgraded to Buy from Neutral at UBS
05/28/21 Barclays
Kansas City Southern downgraded to Underweight from Equal Weight at Barclays
05/27/21 Scotiabank
Canadian National upgraded to Outperform at Scotiabank after 12% pullback
KSU Kansas City Southern
$292.28 /

-1.645 (-0.56%)

KSU Kansas City Southern
$292.28 /

-1.645 (-0.56%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

KSU Kansas City Southern
$292.28 /

-1.645 (-0.56%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

Hot Stocks
Jounce Therapeutics achieves first milestone in license agreement with Gilead » 08:04
06/15/21
06/15
08:04
06/15/21
08:04
JNCE

Jounce Therapeutics

$6.98 /

-0.07 (-0.99%)

, GILD

Gilead

$68.15 /

+0.09 (+0.13%)

Jounce Therapeutics…

Jounce Therapeutics (JNCE) announced the Food and Drug Administration's clearance of its Investigational New Drug application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences (GILD) has exclusive rights to develop and commercialize. The IND clearance triggers a $25M milestone payment to Jounce. Under the terms of the September 2020 agreement, Gilead invested $35M in Jounce's common stock and made an $85M upfront payment to Jounce. Jounce has led the development of JTX-1811 through IND clearance, after which Gilead now has the sole right to develop and commercialize the program. After receiving this $25M milestone payment, Jounce may receive up to an additional $660M in future clinical, regulatory and commercial milestone payments and will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales. Any milestone or royalty paid to Jounce is subject to certain reductions as described in the license agreement.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
GILD Gilead
$68.15 /

+0.09 (+0.13%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

  • 10
    Mar
GILD Gilead
$68.15 /

+0.09 (+0.13%)

JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/15/21
06/15
04:55
06/15/21
04:55
APTO

Aptose Biosciences

$3.71 /

-0.04 (-1.07%)

, MBIO

Mustang Bio

$3.68 /

-0.11 (-2.90%)

, QURE

uniQure

$34.89 /

-1.24 (-3.43%)

, RIGL

Rigel Pharmaceuticals

$4.37 /

+0.35 (+8.71%)

, MGTA

Magenta Therapeutics

$11.33 /

-0.22 (-1.90%)

, MEIP

MEI Pharma

$3.28 /

+0.005 (+0.15%)

, CRIS

Curis

$8.05 /

+0.05 (+0.63%)

, XLRN

Acceleron

$131.02 /

-2.4 (-1.80%)

, EPZM

Epizyme

$8.81 /

+0.305 (+3.59%)

, INCY

Incyte

$82.61 /

+0.03 (+0.04%)

, ORTX

Orchard Therapeutics

$5.04 /

-0.09 (-1.75%)

, TGTX

TG Therapeutics

$38.30 /

+0.49 (+1.30%)

, EQ

Equillium

$6.00 /

-0.12 (-1.96%)

, JAZZ

Jazz Pharmaceuticals

$186.45 /

+0.15 (+0.08%)

, VRTX

Vertex Pharmaceuticals

$194.81 /

+1.78 (+0.92%)

, SGEN

Seagen

$156.25 /

-0.21 (-0.13%)

, IMRA

Imara

$8.70 /

+0.135 (+1.58%)

, GBT

Global Blood Therapeutics

$40.25 /

-0.32 (-0.79%)

, BGNE

BeiGene

$344.52 /

-5.39 (-1.54%)

, APLS

Apellis

$64.90 /

+2.8 (+4.51%)

, AGIO

Agios Pharmaceuticals

$58.20 /

+0.43 (+0.74%)

, FMTX

Forma Therapeutics

$24.22 /

+1.41 (+6.18%)

, KROS

Keros Therapeutics

$53.00 /

+1.64 (+3.19%)

, CYAD

Celyad

$5.41 /

-0.29 (-5.09%)

, ALXN

Alexion

$181.65 /

+0.08 (+0.04%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$131.02 /

-2.4 (-1.80%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

SGEN Seagen
$156.25 /

-0.21 (-0.13%)

RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

QURE uniQure
$34.89 /

-1.24 (-3.43%)

ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

MGTA Magenta Therapeutics
$11.33 /

-0.22 (-1.90%)

MEIP MEI Pharma
$3.28 /

+0.005 (+0.15%)

MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

KROS Keros Therapeutics
$53.00 /

+1.64 (+3.19%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

IMRA Imara
$8.70 /

+0.135 (+1.58%)

GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

CYAD Celyad
$5.41 /

-0.29 (-5.09%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

BGNE BeiGene
$344.52 /

-5.39 (-1.54%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

AGIO Agios Pharmaceuticals
$58.20 /

+0.43 (+0.74%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.89 /

-1.24 (-3.43%)

06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.33 /

-0.22 (-1.90%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.28 /

+0.005 (+0.15%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$8.05 /

+0.05 (+0.63%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$131.02 /

-2.4 (-1.80%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.61 /

+0.03 (+0.04%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.00 /

-0.12 (-1.96%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$156.25 /

-0.21 (-0.13%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.70 /

+0.135 (+1.58%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$344.52 /

-5.39 (-1.54%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$64.90 /

+2.8 (+4.51%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.20 /

+0.43 (+0.74%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$53.00 /

+1.64 (+3.19%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.41 /

-0.29 (-5.09%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.65 /

+0.08 (+0.04%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$131.02 /

-2.4 (-1.80%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

SGEN Seagen
$156.25 /

-0.21 (-0.13%)

RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

QURE uniQure
$34.89 /

-1.24 (-3.43%)

ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

MGTA Magenta Therapeutics
$11.33 /

-0.22 (-1.90%)

MEIP MEI Pharma
$3.28 /

+0.005 (+0.15%)

MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

KROS Keros Therapeutics
$53.00 /

+1.64 (+3.19%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

IMRA Imara
$8.70 /

+0.135 (+1.58%)

GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

BGNE BeiGene
$344.52 /

-5.39 (-1.54%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

AGIO Agios Pharmaceuticals
$58.20 /

+0.43 (+0.74%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

SGEN Seagen
$156.25 /

-0.21 (-0.13%)

QURE uniQure
$34.89 /

-1.24 (-3.43%)

MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

IMRA Imara
$8.70 /

+0.135 (+1.58%)

GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

Monday
Hot Stocks
Global Blood Therapeutics receives PIM designation for voxelotor from UK » 07:17
06/14/21
06/14
07:17
06/14/21
07:17
GBT

Global Blood Therapeutics

$40.64 /

-1.01 (-2.42%)

Global Blood Therapeutics…

Global Blood Therapeutics announced that the Medicines and Healthcare Products Regulatory Agency, or MHRA, in the United Kingdom has granted a Promising Innovative Medicine, or PIM, designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease. Following a review by the MHRA, PIM designations are given to promising treatments that are likely to offer a major advantage for patients and are an early indication that the treatment is a promising candidate for the Early Access to Medicines Scheme. Voxelotor is approved in the United States under the trade name Oxbryta for the treatment of SCD in patients ages 12 years and older. GBT previously announced its plans to seek regulatory approval from the European Medicines Agency for voxelotor in the treatment of hemolytic anemia in SCD patients ages 12 years and older. Prior to potential marketing authorization, GBT initiated an early access program for voxelotor in Europe and other regions outside the United States, which enables physicians to use early access regulatory and legal pathways to request voxelotor for the treatment of hemolytic anemia in eligible patients with SCD who do not have access to the medicine as part of a clinical trial. If approved for EAMS, the voxelotor early access program would be further extended to eligible UK patients.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/14/21
06/14
04:55
06/14/21
04:55
APTO

Aptose Biosciences

$3.75 /

-1.79 (-32.31%)

, MBIO

Mustang Bio

$3.79 /

-0.03 (-0.79%)

, QURE

uniQure

$36.05 /

-0.63 (-1.72%)

, RIGL

Rigel Pharmaceuticals

$4.02 /

-0.16 (-3.83%)

, MGTA

Magenta Therapeutics

$11.57 /

-0.15 (-1.28%)

, MEIP

MEI Pharma

$3.28 /

+0.08 (+2.50%)

, CRIS

Curis

$8.00 /

-4.72 (-37.11%)

, XLRN

Acceleron

$133.36 /

+2.36 (+1.80%)

, EPZM

Epizyme

$8.53 /

+0.08 (+0.95%)

, INCY

Incyte

$82.59 /

-4.97 (-5.68%)

, ORTX

Orchard Therapeutics

$5.12 /

-0.05 (-0.97%)

, TGTX

TG Therapeutics

$37.81 /

-0.14 (-0.37%)

, EQ

Equillium

$6.12 /

-0.85 (-12.20%)

, JAZZ

Jazz Pharmaceuticals

$186.19 /

-0.21 (-0.11%)

, VRTX

Vertex Pharmaceuticals

$193.02 /

-23.93 (-11.03%)

, SGEN

Seagen

$156.27 /

-2.3 (-1.45%)

, IMRA

Imara

$8.56 /

-0.235 (-2.67%)

, GBT

Global Blood Therapeutics

$40.64 /

-1.01 (-2.42%)

, BGNE

BeiGene

$346.81 /

-6.09 (-1.73%)

, APLS

Apellis

$62.10 /

+1.33 (+2.19%)

, AGIO

Agios Pharmaceuticals

$57.80 /

-1.69 (-2.84%)

, FMTX

Forma Therapeutics

$22.81 /

-5.2 (-18.56%)

, KROS

Keros Therapeutics

$51.75 /

-0.61 (-1.17%)

, CYAD

Celyad

$5.75 /

-0.22 (-3.69%)

, ALXN

Alexion

$181.64 /

-0.41 (-0.23%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CYAD Celyad
$5.75 /

-0.22 (-3.69%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$36.05 /

-0.63 (-1.72%)

05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$8.00 /

-4.72 (-37.11%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.59 /

-4.97 (-5.68%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.12 /

-0.85 (-12.20%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
SGEN Seagen
$156.27 /

-2.3 (-1.45%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.56 /

-0.235 (-2.67%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
APLS Apellis
$62.10 /

+1.33 (+2.19%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.75 /

-0.22 (-3.69%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.64 /

-0.41 (-0.23%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

Sunday
Hot Stocks
Kite announces follow-up results from ZUMA-5 trial of Yescarta » 16:02
06/13/21
06/13
16:02
06/13/21
16:02
GILD

Gilead

$68.77 /

-0.54 (-0.78%)

Kite, a Gilead company,…

Kite, a Gilead company, announced follow-up results from the pivotal ZUMA-5 trial of Yescarta - the first and only CAR T-cell therapy approved in patients with relapsed or refractory indolent follicular lymphoma. At a minimum follow-up of 18 months, 94% of patients had achieved a response, and secondary endpoints of median progression-free survival and overall survival were not yet reached. In a weighted analysis comparing ZUMA-5 patients with a minimum of 18 months follow-up with those observed in SCHOLAR-5, an external control cohort, Yescarta demonstrated superior OS and PFS over currently available treatments. These data were presented as a part of a late-breaking session at the 26th Annual Meeting of the European Hematology Association taking place virtually this year from June 9-17. The propensity score analysis compared follow-up data from the pivotal Phase 2 ZUMA-5 study to a weighted sample from the SCHOLAR-5 external control cohort of current therapies, balanced for patient characteristics through propensity scoring. Ninety-four percent of patients in the ZUMA-5 cohort achieved a response compared to 50% of patients in the control cohort, with an odds ratio of 16.2. Yescarta demonstrated a 58% reduction in the risk of death and 70% reduction in the risk of disease progression, relapse or death versus current therapies in the control cohort. While median OS and PFS were both not reached in ZUMA-5, median PFS and OS were 12.7 months and 59.8 months, respectively, in the control cohort. In the ZUMA-5 safety analysis set, Grade 3 or higher cytokine release syndrome and neurologic toxicities occurred in 8% and 21% of patients, respectively. Yescarta received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in March 2021. The Yescarta U.S. Prescribing Information has a BOXED WARNING for the risks of CRS and neurologic toxicities, and Yescarta is approved with a risk evaluation and mitigation strategy due to these risks; see below for Important Safety Information.

ShowHide Related Items >><<
GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/13/21
06/13
04:55
06/13/21
04:55
APTO

Aptose Biosciences

$3.75 /

-1.79 (-32.31%)

, MBIO

Mustang Bio

$3.79 /

-0.03 (-0.79%)

, QURE

uniQure

$36.05 /

-0.63 (-1.72%)

, RIGL

Rigel Pharmaceuticals

$4.02 /

-0.16 (-3.83%)

, MGTA

Magenta Therapeutics

$11.57 /

-0.15 (-1.28%)

, MEIP

MEI Pharma

$3.28 /

+0.08 (+2.50%)

, CRIS

Curis

$8.00 /

-4.72 (-37.11%)

, XLRN

Acceleron

$133.36 /

+2.36 (+1.80%)

, EPZM

Epizyme

$8.53 /

+0.08 (+0.95%)

, INCY

Incyte

$82.59 /

-4.97 (-5.68%)

, ORTX

Orchard Therapeutics

$5.12 /

-0.05 (-0.97%)

, TGTX

TG Therapeutics

$37.81 /

-0.14 (-0.37%)

, EQ

Equillium

$6.12 /

-0.85 (-12.20%)

, JAZZ

Jazz Pharmaceuticals

$186.19 /

-0.21 (-0.11%)

, VRTX

Vertex Pharmaceuticals

$193.02 /

-23.93 (-11.03%)

, SGEN

Seagen

$156.27 /

-2.3 (-1.45%)

, IMRA

Imara

$8.56 /

-0.235 (-2.67%)

, GBT

Global Blood Therapeutics

$40.64 /

-1.01 (-2.42%)

, BGNE

BeiGene

$346.81 /

-6.09 (-1.73%)

, APLS

Apellis

$62.10 /

+1.33 (+2.19%)

, AGIO

Agios Pharmaceuticals

$57.80 /

-1.69 (-2.84%)

, FMTX

Forma Therapeutics

$22.81 /

-5.2 (-18.56%)

, KROS

Keros Therapeutics

$51.75 /

-0.61 (-1.17%)

, CYAD

Celyad

$5.75 /

-0.22 (-3.69%)

, ALXN

Alexion

$181.64 /

-0.41 (-0.23%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CYAD Celyad
$5.75 /

-0.22 (-3.69%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$36.05 /

-0.63 (-1.72%)

05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$8.00 /

-4.72 (-37.11%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.59 /

-4.97 (-5.68%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.12 /

-0.85 (-12.20%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
06/11/21 Cantor Fitzgerald
Vertex Pharmaceuticals price target lowered to $281 from $285 at Cantor Fitzgerald
SGEN Seagen
$156.27 /

-2.3 (-1.45%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.56 /

-0.235 (-2.67%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
APLS Apellis
$62.10 /

+1.33 (+2.19%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.75 /

-0.22 (-3.69%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.64 /

-0.41 (-0.23%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

Saturday
Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/12/21
06/12
04:55
06/12/21
04:55
APTO

Aptose Biosciences

$3.75 /

-1.79 (-32.31%)

, MBIO

Mustang Bio

$3.79 /

-0.03 (-0.79%)

, QURE

uniQure

$36.05 /

-0.63 (-1.72%)

, RIGL

Rigel Pharmaceuticals

$4.02 /

-0.16 (-3.83%)

, MGTA

Magenta Therapeutics

$11.57 /

-0.15 (-1.28%)

, MEIP

MEI Pharma

$3.28 /

+0.08 (+2.50%)

, CRIS

Curis

$8.00 /

-4.72 (-37.11%)

, XLRN

Acceleron

$133.36 /

+2.36 (+1.80%)

, EPZM

Epizyme

$8.53 /

+0.08 (+0.95%)

, INCY

Incyte

$82.59 /

-4.97 (-5.68%)

, ORTX

Orchard Therapeutics

$5.12 /

-0.05 (-0.97%)

, TGTX

TG Therapeutics

$37.81 /

-0.14 (-0.37%)

, EQ

Equillium

$6.12 /

-0.85 (-12.20%)

, JAZZ

Jazz Pharmaceuticals

$186.19 /

-0.21 (-0.11%)

, VRTX

Vertex Pharmaceuticals

$193.02 /

-23.93 (-11.03%)

, SGEN

Seagen

$156.27 /

-2.3 (-1.45%)

, IMRA

Imara

$8.56 /

-0.235 (-2.67%)

, GBT

Global Blood Therapeutics

$40.64 /

-1.01 (-2.42%)

, BGNE

BeiGene

$346.81 /

-6.09 (-1.73%)

, APLS

Apellis

$62.10 /

+1.33 (+2.19%)

, AGIO

Agios Pharmaceuticals

$57.80 /

-1.69 (-2.84%)

, FMTX

Forma Therapeutics

$22.81 /

-5.2 (-18.56%)

, KROS

Keros Therapeutics

$51.75 /

-0.61 (-1.17%)

, CYAD

Celyad

$5.75 /

-0.22 (-3.69%)

, ALXN

Alexion

$181.64 /

-0.41 (-0.23%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CYAD Celyad
$5.75 /

-0.22 (-3.69%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$36.05 /

-0.63 (-1.72%)

05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
01/07/21
Fly Intel: Top five analyst initiations
MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$8.00 /

-4.72 (-37.11%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.59 /

-4.97 (-5.68%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.12 /

-0.85 (-12.20%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
06/11/21 Cantor Fitzgerald
Vertex Pharmaceuticals price target lowered to $281 from $285 at Cantor Fitzgerald
SGEN Seagen
$156.27 /

-2.3 (-1.45%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.56 /

-0.235 (-2.67%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
APLS Apellis
$62.10 /

+1.33 (+2.19%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.75 /

-0.22 (-3.69%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.64 /

-0.41 (-0.23%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$133.36 /

+2.36 (+1.80%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

MGTA Magenta Therapeutics
$11.57 /

-0.15 (-1.28%)

MEIP MEI Pharma
$3.28 /

+0.08 (+2.50%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

KROS Keros Therapeutics
$51.75 /

-0.61 (-1.17%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

BGNE BeiGene
$346.81 /

-6.09 (-1.73%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

AGIO Agios Pharmaceuticals
$57.80 /

-1.69 (-2.84%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

RIGL Rigel Pharmaceuticals
$4.02 /

-0.16 (-3.83%)

ORTX Orchard Therapeutics
$5.12 /

-0.05 (-0.97%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

EPZM Epizyme
$8.53 /

+0.08 (+0.95%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

TGTX TG Therapeutics
$37.81 /

-0.14 (-0.37%)

SGEN Seagen
$156.27 /

-2.3 (-1.45%)

QURE uniQure
$36.05 /

-0.63 (-1.72%)

MBIO Mustang Bio
$3.79 /

-0.03 (-0.79%)

JAZZ Jazz Pharmaceuticals
$186.19 /

-0.21 (-0.11%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

IMRA Imara
$8.56 /

-0.235 (-2.67%)

GBT Global Blood Therapeutics
$40.64 /

-1.01 (-2.42%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APTO Aptose Biosciences
$3.75 /

-1.79 (-32.31%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

INCY Incyte
$82.59 /

-4.97 (-5.68%)

FMTX Forma Therapeutics
$22.81 /

-5.2 (-18.56%)

EQ Equillium
$6.12 /

-0.85 (-12.20%)

CRIS Curis
$8.00 /

-4.72 (-37.11%)

APLS Apellis
$62.10 /

+1.33 (+2.19%)

ALXN Alexion
$181.64 /

-0.41 (-0.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.